Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. JP2020117502 - METHOD OF TREATING SIGNS AND SYMPTOMS OF OSTEOARTHRITIS

Office
Japon
Numéro de la demande 2020009842
Date de la demande 24.01.2020
Numéro de publication 2020117502
Date de publication 06.08.2020
Type de publication A
CPC
A61K 39/3955
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
39533against materials from animals
3955against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
Déposants PFIZER INC
ファイザー・インク
Inventeurs CHRISTINE RUTH WEST
クリスチャン ルース ウェスト
MARK THOMAS BROWN
マーク トーマス ブラウン
Mandataires 四本 能尚
宮澤 純子
佐藤 眞紀
龍田 美幸
池田 理愛
Données relatives à la priorité 62/797537 28.01.2019 US
62/835297 17.04.2019 US
62/851988 23.05.2019 US
62/923663 21.10.2019 US
62/947113 12.12.2019 US
62/949777 18.12.2019 US
Titre
(EN) METHOD OF TREATING SIGNS AND SYMPTOMS OF OSTEOARTHRITIS
(JA) 変形性関節症の徴候および症状を処置する方法
Abrégé
(EN)

PROBLEM TO BE SOLVED: To provide treatment of signs and symptoms of osteoarthritis with an anti-nerve growth factor (NGF) antibody.

SOLUTION: A method for treating signs and symptoms of osteoarthritis (OA) in a patient comprises administering to the patient an anti-nerve growth factor (NGF) antibody at a dose of 2.5 mg or 5 mg every 8 weeks via subcutaneous injection; where the patient has a history of inadequate pain relief or intolerance to analgesic therapy and where the treatment with the anti-NGF antibody effectively improves signs and symptoms of OA by at least 16 weeks after the start of the treatment with the anti-NGF antibody.

SELECTED DRAWING: Figure 3

COPYRIGHT: (C)2020,JPO&INPIT

(JA)

【課題】本発明は、抗神経成長因子(NGF)抗体を用いた変形性関節症の徴候および症状の処置を提供すること。
【解決手段】患者において変形性関節症(OA)の徴候および症状を処置するための方法であって、皮下注射を介して8週間毎に2.5mgまたは5mgの用量の抗神経成長因子(NGF)抗体を患者に投与するステップを含み;患者が、不適切な疼痛緩和または鎮痛療法に対する不耐性の履歴を有し、抗NGF抗体による処置が、抗NGF抗体による処置の開始の少なくとも16週間後までに、OAの徴候および症状を効果的に改善する、方法を提供する。
【選択図】図3

Related patent documents
IL285169This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
RU2021122145This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
KR1020217027030This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
EP2020703532This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.